Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Chinook Therapeutics	Kadmon	Emisphere Technologies	Calliditas Therapeutics AB (publ)	Veru
Symbol	NASDAQ:KDNY	NASDAQ:KDMN	OTCMKTS:EMIS	NASDAQ:CALT	NASDAQ:VERU
Price Information
Current Price	$15.15	$3.58	$7.81	$27.02	$7.24
52 Week Range	Buy	Buy	N/A	Buy	Buy
MarketRank™
Overall Score	1.4	1.8	0.9	1.3	1.4
Analysis Score	3.5	3.5	0.0	3.5	3.5
Community Score	2.8	3.2	2.6	2.6	2.9
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	1.7	1.7	0.0	0.0
Earnings & Valuation Score	0.6	0.6	0.0	0.6	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	N/A	Buy	Buy
Consensus Price Target	$30.33	$12.75	N/A	$40.80	$19.20
% Upside from Price Target	100.22% upside	256.15% upside	N/A	51.00% upside	165.19% upside
Trade Information
Market Cap	$642.10 million	$615.67 million	$673.08 million	$674.72 million	$520.64 million
Beta	0.26	1.68	1.38	N/A	0.71
Average Volume	181,243	3,336,147	75,743	39,975	3,561,127
Sales & Book Value
Annual Revenue	$17.26 million	$5.09 million	N/A	$19.56 million	$42.59 million
Price / Sales	37.20	120.96	N/A	34.49	12.22
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$4.07 per share	$0.95 per share	N/A	N/A	$0.43 per share
Price / Book	3.72	3.77	N/A	∞	16.84
Profitability
Net Income	$-82,370,000.00	$-61,370,000.00	N/A	$-3,450,000.00	$-18,970,000.00
EPS	($5.15)	($0.74)	N/A	($0.19)	($0.11)
Trailing P/E Ratio	N/A	N/A	0.00	N/A	N/A
Forward P/E Ratio	N/A	N/A	∞	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-215.80%	-768.36%	N/A	N/A	-44.55%
Return on Equity (ROE)	-112.72%	-85.07%	N/A	-26.80%	-23.72%
Return on Assets (ROA)	-21.36%	-46.46%	N/A	-25.38%	-13.80%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	0.02%	N/A	N/A	N/A
Current Ratio	11.27%	5.76%	N/A	23.46%	1.83%
Quick Ratio	11.27%	5.76%	N/A	23.46%	1.38%
Ownership Information
Institutional Ownership Percentage	N/A	94.78%	0.02%	11.85%	23.32%
Insider Ownership Percentage	5.90%	2.95%	72.90%	N/A	26.10%
Miscellaneous
Employees	105	127	6	34	339
Shares Outstanding	42.38 million	171.97 million	86.18 million	24.97 million	71.91 million
Next Earnings Date	5/17/2021 (Estimated)	8/5/2021 (Estimated)	N/A	5/13/2021 (Estimated)	5/12/2021 (Confirmed)
Optionable	Optionable	Optionable	Not Optionable	Not Optionable	Optionable

Source	Headline
	Veru, Inc. (VERU) CEO Mitchell Steiner on Q2 2021 Results - Earnings Call Transcript - Seeking Alpha seekingalpha.com - May 12 at 8:44 PM
	Veru Inc. (VERU) Q2 2021 Earnings Call Transcript - AlphaStreet news.alphastreet.com - May 12 at 3:44 PM
	Veru Inc. (VERU) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance finance.yahoo.com - May 12 at 3:44 PM
	Veru Inc. (VERU) Reports Q2 Loss, Misses Revenue Estimates finance.yahoo.com - May 12 at 3:44 PM
	$VERU Veru Reports Q2 Loss Per Share Of $0.04 - CML News cmlviz.com - May 12 at 10:43 AM
	Veru: Q2 Earnings Insights - Benzinga benzinga.com - May 12 at 10:43 AM
	Veru Reports Strong Second-Quarter Financial Results Based - GlobeNewswire globenewswire.com - May 12 at 10:43 AM
	Veru Reports Strong Second-Quarter Financial Results Based on Record High FC2 Prescription Revenues finance.yahoo.com - May 12 at 10:43 AM
	What Makes ING (ING) a Good Fit for "Trend Investing" - Nasdaq nasdaq.com - May 11 at 1:32 PM
	My Plea to Investors Right Now - Nasdaq nasdaq.com - May 10 at 8:57 PM
	Builders FirstSource (BLDR) Buys John's Lumber, Boosts Presence - Nasdaq nasdaq.com - May 10 at 3:55 PM
	Why Veru (VERU) Might Surprise This Earnings Season - Yahoo Finance finance.yahoo.com - May 10 at 3:55 PM
	Why Veru (VERU) Might Surprise This Earnings Season finance.yahoo.com - May 10 at 3:55 PM
	Where Does Veru Inc (VERU) Stock Fall in the Biotechnology Field After It Is Down -11.76% This Week? - InvestorsObserver investorsobserver.com - May 7 at 5:39 PM
	Veru (NASDAQ:VERU) Trading 8.6% Higher americanbankingnews.com - May 7 at 12:56 PM
	Veru Inc. (NASDAQ:VERU) Forecasted to Earn FY2022 Earnings of $0.00 Per Share americanbankingnews.com - May 7 at 11:35 AM
	Veru (NASDAQ:VERU) Stock Price Down 11.9% americanbankingnews.com - May 6 at 1:54 PM
	Premarket Mover: Veru Inc (VERU) Up 14.56% - InvestorsObserver investorsobserver.com - May 6 at 8:53 AM
	$14.36 Million in Sales Expected for Veru Inc. (NASDAQ:VERU) This Quarter americanbankingnews.com - May 6 at 4:48 AM
	Clinical News: MDMA and Therapy Significantly Benefits PTSD Patients and More - BioSpace biospace.com - May 5 at 5:52 PM
	Veru (VERU) Stock Rises After Enobosarm Shows Clinical Benefits in Phase 2 Trial - InvestorsObserver investorsobserver.com - May 5 at 5:52 PM
	Veru Inc. (VERU) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance finance.yahoo.com - May 5 at 5:52 PM
	Veru Inc. (VERU) Expected to Beat Earnings Estimates: Should You Buy? finance.yahoo.com - May 5 at 5:52 PM
	Veru Announces the Presentation of Positive Phase 2 Clinical Data of Enobosarm in AR+ER+HER2- Metastatic Breast Cancer Patients that Have Progressed on Estrogen Blocking Agents and CDK 4/6 Inhibitor at the ESMO Breast Cancer Congress 2021 - Yahoo Finance finance.yahoo.com - May 5 at 12:51 PM
	Veru Announces the Presentation of Positive Phase 2 Clinical Data of Enobosarm in AR+ER+HER2- Metastatic Breast Cancer Patients that Have Progressed on Estrogen Blocking Agents and CDK 4/6 Inhibitor at the ESMO Breast Cancer Congress 2021 finance.yahoo.com - May 5 at 12:51 PM

Date	Company	Brokerage	Action
3/22/2021	Chinook Therapeutics	Bloom Burton	Reiterated Rating
1/6/2021	Chinook Therapeutics	Wedbush	Initiated Coverage
12/9/2020	Chinook Therapeutics	Cantor Fitzgerald	Initiated Coverage
11/16/2020	Chinook Therapeutics	HC Wainwright	Initiated Coverage
11/2/2020	Chinook Therapeutics	Evercore ISI	Initiated Coverage
10/20/2020	Chinook Therapeutics	Oppenheimer	Upgrade
10/7/2020	Chinook Therapeutics	SVB Leerink	Initiated Coverage
10/6/2020	Chinook Therapeutics	William Blair	Reiterated Rating
3/11/2021	Kadmon	Raymond James	Boost Price Target
11/11/2020	Kadmon	Mizuho	Initiated Coverage
1/10/2020	Kadmon	Nomura Securities	Initiated Coverage
2/26/2019	Kadmon	Citigroup	Upgrade
10/17/2018	Kadmon	WBB Securities	Upgrade
8/18/2020	Calliditas Therapeutics AB (publ)	Ci Capital	Reiterated Rating
6/30/2020	Calliditas Therapeutics AB (publ)	Jefferies Financial Group	Initiated Coverage
6/30/2020	Calliditas Therapeutics AB (publ)	Stifel Nicolaus	Initiated Coverage
12/14/2020	Veru	Brookline Capital Management	Boost Price Target
3/20/2019	Veru	CIBC	Initiated Coverage

(Data available from 5/12/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources